Illumina (ILMN) to Release Earnings on Thursday

Illumina (NASDAQ:ILMN) will be issuing its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.03 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. Illumina’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.14 earnings per share. On average, analysts expect Illumina to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Illumina Stock Performance

Illumina stock opened at $124.73 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average of $131.14 and a 200-day moving average of $127.20. The firm has a market cap of $19.86 billion, a P/E ratio of -16.99 and a beta of 1.19. Illumina has a 1-year low of $89.00 and a 1-year high of $213.91.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen bought 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were acquired at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.17% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Barclays raised their price objective on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. OTR Global reissued a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Stephens reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, TD Cowen cut shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a research note on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus price target of $167.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.